Pharvaris BV (PHVS) is a Healthcare · Biotechnology company listed on NASDAQ. Price $36.62 (-3.63%), Market cap $2.12B, 52-week low–high $15.46 ~ $32.94.
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headqua
Financial statements, price targets, institutional (13F) holdings and related news for Pharvaris BV are updated in real time on BlackAll Trade.
Pharvaris BV trades at $36.62 (-3.63%). Real-time quotes and charts are available on BlackAll Trade.
Pharvaris BV has a market cap of about $2.12B.
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediat